Drug Trial Radar · NCT07606937
A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Apr 29, 2026
Primary completion
Nov 30, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Shenzhen Fosun Kairos Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 26, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single-arm, multicenter, open-label clinical study evaluating the efficacy and safety of axicabtagene ciloleucel injection manufactured by an automated cell preparation process in adult subjects with relapsed or refractory large B-cell lymphoma (r/r LBCL) as second-line therapy.
Conditions
- Relapsed/Refractory Large B-cell Lymphoma
Interventions
FKC876 injectionDrug
CD19 CAR-T
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Up to 24 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
The Frist Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Shanghai Jiaotong University School of Medicine Ruijin Hospital
Shanghai, Shanghai Municipality, China
West China Hospotal Sichuan University
Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.